| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Department of Polymer Chemistry,*
Advanced
Research Institute for Science and Engineering, Waseda University,
Tokyo; and the Departments of Surgery
and Pathology,
Keio University School of
Medicine, Tokyo, Japan
Hemoglobin-vesicles (HbV) have been developed for use as artificial oxygen carriers (particle diameter, 250 nm) in which a purified Hb solution is encapsulated with a phospholipid bilayer membrane. The influence of HbV on the reticuloendothelial system was studied by carbon clearance measurements and histopathological examination. The HbV suspension ([Hb] = 10 g/dl) was intravenously infused in male Wistar rats at dose rates of 10 and 20 ml/kg, and the phagocytic activity was measured by monitoring the rate of carbon clearance at 8 hours and at 1, 3, 7, and 14 days after infusion. The phagocytic activity transiently decreased one day after infusion by about 40%, but it recovered and was enhanced at 3 days, showing a maximum of about twice the quiescent level at 7 days, and then returned to the normal value at 14 days. The initial transient decreased activity indicates a partly, but not completely, suppressed defensive function of the body. The succeeding increased phagocytic activity corresponds to the increased metabolism of HbV. The histopathological examination with anti-human Hb antibody, hematoxylin/eosin, and oil red O stainings showed that HbV was metabolized within 7 days. Hemosiderin was very slightly confirmed with Berlin blue staining at 3 and 7 days in liver and spleen, though they completely disappeared at 14 days, indicating that the heme metabolism, excretion or recycling of iron proceeded smoothly and iron deposition was minimal. Electron microscopic examination of the spleen and liver tissues clearly demonstrated the particles of HbV with a diameter of about 1/40 of red blood cells in capillaries, and in phagosomes as entrapped in the spleen macrophages and Kupffer cells one day after infusion. The vesicular structure could not be observed at 7 days. Even though the infusion of HbV modified the phagocytic activity for 2 weeks, it does not seem to cause any irreversible damage to the phagocytic organs. These results offer important information for evaluating the safety issues of HbV for clinical use.
This article has been cited by other articles:
 |
|
 |
|
  V. Awasthi, S.-H. Yee, P. Jerabek, B. Goins, and W. T. Phillips Cerebral oxygen delivery by liposome-encapsulated hemoglobin: a positron-emission tomographic evaluation in a rat model of hemorrhagic shock J Appl Physiol, July 1, 2007; 103(1): 28 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yamazaki, R. Aeba, R. Yozu, and K. Kobayashi Use of Hemoglobin Vesicles During Cardiopulmonary Bypass Priming Prevents Neurocognitive Decline in Rats Circulation, July 4, 2006; 114(1_suppl): I-220 - I-225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Sakai, P. Cabrales, A. G. Tsai, E. Tsuchida, and M. Intaglietta Oxygen release from low and normal P50 Hb vesicles in transiently occluded arterioles of the hamster window model Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2897 - H2903. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Matsumoto, T. Asano, K. Mano, H. Tachibana, M. Todoh, M. Tanaka, and F. Kajiya Regional myocardial perfusion under exchange transfusion with liposomal hemoglobin: in vivo and in vitro studies using rat hearts Am J Physiol Heart Circ Physiol, April 1, 2005; 288(4): H1909 - H1914. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Sou, R. Klipper, B. Goins, E. Tsuchida, and W. T. Phillips Circulation Kinetics and Organ Distribution of Hb-Vesicles Developed as a Red Blood Cell Substitute J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 702 - 709. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Sakai, Y. Masada, H. Horinouchi, E. Ikeda, K. Sou, S. Takeoka, M. Suematsu, M. Takaori, K. Kobayashi, and E. Tsuchida Physiological Capacity of the Reticuloendothelial System for the Degradation of Hemoglobin Vesicles (Artificial Oxygen Carriers) after Massive Intravenous Doses by Daily Repeated Infusions for 14 Days J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 874 - 884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Sakai, Y. Suzuki, M. Kinoshita, S. Takeoka, N. Maeda, and E. Tsuchida O2 release from Hb vesicles evaluated using an artificial, narrow O2-permeable tube: comparison with RBCs and acellular Hbs Am J Physiol Heart Circ Physiol, December 1, 2003; 285(6): H2543 - H2551. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Sakai, S. Takeoka, R. Wettstein, A. G. Tsai, M. Intaglietta, and E. Tsuchida Systemic and microvascular responses to hemorrhagic shock and resuscitation with Hb vesicles Am J Physiol Heart Circ Physiol, September 1, 2002; 283(3): H1191 - H1199. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
